[{"edinetCode":"E00975","endDate":"2017\/9\/30","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1480.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":10343000.0,"sharesOwendPercent":0.6619,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":2178.46,"equityRatio":0.658,"cashAndCashEquivalents":5503000000.0,"assets":49551000000.0,"currentAssets":33208000000.0,"fixedAsset":16342000000.0,"tangibleFixedAssets":11703000000.0,"intangibleFixedAssets":2709000000.0,"investmentAndOtherAssets":1930000000.0,"liabilities":16949000000.0,"currentLiabilities":11513000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":653000000.0,"fixedLiabilities":5436000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2000000000.0,"netAsset":32601000000.0,"capitalStock":31887000000.0,"capital":3799000000.0,"capitalSurplus":5023000000.0,"accumulatedEarnings":24541000000.0,"treasuryStock":-1476000000.0,"valuationAndConversionAdjustments":711000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":35387000000.0,"costOfSales":20671000000.0,"grossProfit":14715000000.0,"sgaExpenses":10401000000.0,"salaryAndBenefit":null,"depreciationAndSGA":463000000.0,"RDExpenses":1825000000.0,"operatingIncome":4314000000.0,"nonOperatingIncome":359000000.0,"nonOperatingExpenses":45000000.0,"interestExpense":34000000.0,"ordinaryProfit":4628000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":98000000.0,"incomeBeforeTax":4530000000.0,"incomeTaxes":1228000000.0,"netIncome":3301000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3301000000.0,"comprehensiveIncome":4067000000.0,"eps":220.63,"dilutedEps":null,"dividendPerShare":null,"per":17.4,"roe":0.107,"cashFlowFromOperatingActivities":3238000000.0,"depreciationAndCashflowFromOperatingActivities":1769000000.0,"cashFlowFromInvestingActivities":-1534000000.0,"cashFlowFromFinancialActivities":-3042000000.0,"changesInCashAndCashEquivalents":-1311000000.0,"列1":"asr","submitDate":"2017\/12\/20","stockCode":4554,"accountingYear":"第53期（自　平成28年10月１日　至　平成29年９月30日）","accountingYearStart":"2016\/10\/1","accountingYearEnd":"2017\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2018\/9\/30","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1511.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":21296000.0,"sharesOwendPercent":0.7107,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":1181.37,"equityRatio":0.665,"cashAndCashEquivalents":6251000000.0,"assets":53117000000.0,"currentAssets":35507000000.0,"fixedAsset":17610000000.0,"tangibleFixedAssets":11700000000.0,"intangibleFixedAssets":2220000000.0,"investmentAndOtherAssets":3689000000.0,"liabilities":17767000000.0,"currentLiabilities":11546000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":6220000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2000000000.0,"netAsset":35350000000.0,"capitalStock":34438000000.0,"capital":3799000000.0,"capitalSurplus":5023000000.0,"accumulatedEarnings":27119000000.0,"treasuryStock":-1504000000.0,"valuationAndConversionAdjustments":909000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":37909000000.0,"costOfSales":21959000000.0,"grossProfit":15950000000.0,"sgaExpenses":11559000000.0,"salaryAndBenefit":null,"depreciationAndSGA":470000000.0,"RDExpenses":1760000000.0,"operatingIncome":4391000000.0,"nonOperatingIncome":137000000.0,"nonOperatingExpenses":55000000.0,"interestExpense":38000000.0,"ordinaryProfit":4472000000.0,"extraordinaryGain":5000000.0,"extraordinaryLoss":5000000.0,"incomeBeforeTax":4472000000.0,"incomeTaxes":1099000000.0,"netIncome":3372000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3372000000.0,"comprehensiveIncome":3571000000.0,"eps":112.68,"dilutedEps":null,"dividendPerShare":null,"per":15.9,"roe":0.099,"cashFlowFromOperatingActivities":3773000000.0,"depreciationAndCashflowFromOperatingActivities":1976000000.0,"cashFlowFromInvestingActivities":-1073000000.0,"cashFlowFromFinancialActivities":-2001000000.0,"changesInCashAndCashEquivalents":747000000.0,"列1":"asr","submitDate":"2018\/12\/19","stockCode":4554,"accountingYear":"第54期（自　2017年10月１日　至　2018年９月30日）","accountingYearStart":"2017\/10\/1","accountingYearEnd":"2018\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2019\/3\/31","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":21701000.0,"sharesOwendPercent":0.7242,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.623,"cashAndCashEquivalents":6435000000.0,"assets":59013000000.0,"currentAssets":34753000000.0,"fixedAsset":24259000000.0,"tangibleFixedAssets":11688000000.0,"intangibleFixedAssets":3409000000.0,"investmentAndOtherAssets":9162000000.0,"liabilities":22258000000.0,"currentLiabilities":12383000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":2840000000.0,"fixedLiabilities":9875000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5950000000.0,"netAsset":36754000000.0,"capitalStock":35747000000.0,"capital":3799000000.0,"capitalSurplus":5023000000.0,"accumulatedEarnings":28411000000.0,"treasuryStock":-1486000000.0,"valuationAndConversionAdjustments":1004000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":18483000000.0,"costOfSales":10561000000.0,"grossProfit":7921000000.0,"sgaExpenses":5454000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":699000000.0,"operatingIncome":2467000000.0,"nonOperatingIncome":136000000.0,"nonOperatingExpenses":101000000.0,"interestExpense":19000000.0,"ordinaryProfit":2501000000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":2000000.0,"incomeBeforeTax":2499000000.0,"incomeTaxes":803000000.0,"netIncome":1695000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1695000000.0,"comprehensiveIncome":1790000000.0,"eps":56.66,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":2281000000.0,"depreciationAndCashflowFromOperatingActivities":930000000.0,"cashFlowFromInvestingActivities":-8150000000.0,"cashFlowFromFinancialActivities":6068000000.0,"changesInCashAndCashEquivalents":183000000.0,"列1":"q2r","submitDate":"2019\/5\/10","stockCode":4554,"accountingYear":null,"accountingYearStart":"2018\/10\/1","accountingYearEnd":"2019\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2019\/6\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.641,"cashAndCashEquivalents":null,"assets":60844000000.0,"currentAssets":34232000000.0,"fixedAsset":26612000000.0,"tangibleFixedAssets":11734000000.0,"intangibleFixedAssets":3313000000.0,"investmentAndOtherAssets":11564000000.0,"liabilities":21811000000.0,"currentLiabilities":12229000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":2840000000.0,"fixedLiabilities":9581000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5740000000.0,"netAsset":39033000000.0,"capitalStock":38363000000.0,"capital":3799000000.0,"capitalSurplus":5841000000.0,"accumulatedEarnings":28802000000.0,"treasuryStock":-78000000.0,"valuationAndConversionAdjustments":667000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":27324000000.0,"costOfSales":15388000000.0,"grossProfit":11936000000.0,"sgaExpenses":8210000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3726000000.0,"nonOperatingIncome":150000000.0,"nonOperatingExpenses":162000000.0,"interestExpense":30000000.0,"ordinaryProfit":3714000000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":18000000.0,"incomeBeforeTax":3697000000.0,"incomeTaxes":1175000000.0,"netIncome":2521000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2521000000.0,"comprehensiveIncome":2279000000.0,"eps":83.17,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2019\/8\/9","stockCode":4554,"accountingYear":null,"accountingYearStart":"2018\/10\/1","accountingYearEnd":"2019\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2019\/9\/30","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1527.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":22644000.0,"sharesOwendPercent":0.7261,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":1263.51,"equityRatio":0.648,"cashAndCashEquivalents":8494000000.0,"assets":60737000000.0,"currentAssets":33919000000.0,"fixedAsset":26817000000.0,"tangibleFixedAssets":11718000000.0,"intangibleFixedAssets":3300000000.0,"investmentAndOtherAssets":11798000000.0,"liabilities":21373000000.0,"currentLiabilities":12012000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":2840000000.0,"fixedLiabilities":9360000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5530000000.0,"netAsset":39363000000.0,"capitalStock":38804000000.0,"capital":3799000000.0,"capitalSurplus":5841000000.0,"accumulatedEarnings":29243000000.0,"treasuryStock":-78000000.0,"valuationAndConversionAdjustments":556000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":36279000000.0,"costOfSales":20483000000.0,"grossProfit":15796000000.0,"sgaExpenses":11622000000.0,"salaryAndBenefit":null,"depreciationAndSGA":334000000.0,"RDExpenses":2052000000.0,"operatingIncome":4173000000.0,"nonOperatingIncome":156000000.0,"nonOperatingExpenses":160000000.0,"interestExpense":41000000.0,"ordinaryProfit":4169000000.0,"extraordinaryGain":4000000.0,"extraordinaryLoss":212000000.0,"incomeBeforeTax":3961000000.0,"incomeTaxes":998000000.0,"netIncome":2962000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2962000000.0,"comprehensiveIncome":2609000000.0,"eps":97.04,"dilutedEps":null,"dividendPerShare":null,"per":13.57,"roe":0.079,"cashFlowFromOperatingActivities":7035000000.0,"depreciationAndCashflowFromOperatingActivities":1850000000.0,"cashFlowFromInvestingActivities":-12024000000.0,"cashFlowFromFinancialActivities":7265000000.0,"changesInCashAndCashEquivalents":2243000000.0,"列1":"asr","submitDate":"2019\/12\/19","stockCode":4554,"accountingYear":"第55期（自　2018年10月１日　至　2019年９月30日）","accountingYearStart":"2018\/10\/1","accountingYearEnd":"2019\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2019\/12\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.681,"cashAndCashEquivalents":null,"assets":58907000000.0,"currentAssets":32107000000.0,"fixedAsset":26799000000.0,"tangibleFixedAssets":11714000000.0,"intangibleFixedAssets":3244000000.0,"investmentAndOtherAssets":11841000000.0,"liabilities":18804000000.0,"currentLiabilities":9708000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":840000000.0,"fixedLiabilities":9096000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5320000000.0,"netAsset":40102000000.0,"capitalStock":39092000000.0,"capital":3799000000.0,"capitalSurplus":5841000000.0,"accumulatedEarnings":29520000000.0,"treasuryStock":-68000000.0,"valuationAndConversionAdjustments":1007000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":8968000000.0,"costOfSales":4901000000.0,"grossProfit":4067000000.0,"sgaExpenses":3013000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1053000000.0,"nonOperatingIncome":44000000.0,"nonOperatingExpenses":12000000.0,"interestExpense":10000000.0,"ordinaryProfit":1085000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":0.0,"incomeBeforeTax":1086000000.0,"incomeTaxes":340000000.0,"netIncome":745000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":745000000.0,"comprehensiveIncome":1196000000.0,"eps":23.92,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/2\/7","stockCode":4554,"accountingYear":null,"accountingYearStart":"2019\/10\/1","accountingYearEnd":"2020\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2020\/3\/31","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":22420000.0,"sharesOwendPercent":0.719,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.675,"cashAndCashEquivalents":6046000000.0,"assets":58162000000.0,"currentAssets":31742000000.0,"fixedAsset":26420000000.0,"tangibleFixedAssets":12298000000.0,"intangibleFixedAssets":3046000000.0,"investmentAndOtherAssets":11075000000.0,"liabilities":18900000000.0,"currentLiabilities":10237000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":840000000.0,"fixedLiabilities":8663000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":5110000000.0,"netAsset":39262000000.0,"capitalStock":38657000000.0,"capital":3799000000.0,"capitalSurplus":5841000000.0,"accumulatedEarnings":29086000000.0,"treasuryStock":-68000000.0,"valuationAndConversionAdjustments":601000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":16905000000.0,"costOfSales":9255000000.0,"grossProfit":7650000000.0,"sgaExpenses":5914000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1586000000.0,"operatingIncome":1735000000.0,"nonOperatingIncome":15000000.0,"nonOperatingExpenses":140000000.0,"interestExpense":18000000.0,"ordinaryProfit":1610000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":1187000000.0,"incomeBeforeTax":423000000.0,"incomeTaxes":112000000.0,"netIncome":311000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":310000000.0,"comprehensiveIncome":355000000.0,"eps":9.98,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":2442000000.0,"depreciationAndCashflowFromOperatingActivities":866000000.0,"cashFlowFromInvestingActivities":-1724000000.0,"cashFlowFromFinancialActivities":-3133000000.0,"changesInCashAndCashEquivalents":-2448000000.0,"列1":"q2r","submitDate":"2020\/5\/11","stockCode":4554,"accountingYear":null,"accountingYearStart":"2019\/10\/1","accountingYearEnd":"2020\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2020\/6\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.637,"cashAndCashEquivalents":null,"assets":62602000000.0,"currentAssets":35690000000.0,"fixedAsset":26911000000.0,"tangibleFixedAssets":12432000000.0,"intangibleFixedAssets":3081000000.0,"investmentAndOtherAssets":11397000000.0,"liabilities":22732000000.0,"currentLiabilities":11171000000.0,"shorTermDept":1000000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1640000000.0,"fixedLiabilities":11561000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":8000000000.0,"netAsset":39869000000.0,"capitalStock":39475000000.0,"capital":3799000000.0,"capitalSurplus":5841000000.0,"accumulatedEarnings":29904000000.0,"treasuryStock":-68000000.0,"valuationAndConversionAdjustments":391000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":24899000000.0,"costOfSales":13922000000.0,"grossProfit":10977000000.0,"sgaExpenses":8753000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":2223000000.0,"nonOperatingIncome":20000000.0,"nonOperatingExpenses":92000000.0,"interestExpense":28000000.0,"ordinaryProfit":2151000000.0,"extraordinaryGain":4000000.0,"extraordinaryLoss":15000000.0,"incomeBeforeTax":2139000000.0,"incomeTaxes":573000000.0,"netIncome":1565000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1565000000.0,"comprehensiveIncome":1400000000.0,"eps":50.24,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/8\/7","stockCode":4554,"accountingYear":null,"accountingYearStart":"2019\/10\/1","accountingYearEnd":"2020\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2020\/9\/30","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1550.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":22268000.0,"sharesOwendPercent":0.7141,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":1282.43,"equityRatio":0.645,"cashAndCashEquivalents":12041000000.0,"assets":61962000000.0,"currentAssets":34975000000.0,"fixedAsset":26987000000.0,"tangibleFixedAssets":12767000000.0,"intangibleFixedAssets":2899000000.0,"investmentAndOtherAssets":11320000000.0,"liabilities":22001000000.0,"currentLiabilities":11004000000.0,"shorTermDept":1000000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1640000000.0,"fixedLiabilities":10996000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":7590000000.0,"netAsset":39961000000.0,"capitalStock":39995000000.0,"capital":3799000000.0,"capitalSurplus":5841000000.0,"accumulatedEarnings":30424000000.0,"treasuryStock":-68000000.0,"valuationAndConversionAdjustments":-37000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":33793000000.0,"costOfSales":18921000000.0,"grossProfit":14872000000.0,"sgaExpenses":11732000000.0,"salaryAndBenefit":null,"depreciationAndSGA":341000000.0,"RDExpenses":3060000000.0,"operatingIncome":3139000000.0,"nonOperatingIncome":26000000.0,"nonOperatingExpenses":181000000.0,"interestExpense":37000000.0,"ordinaryProfit":2983000000.0,"extraordinaryGain":4000000.0,"extraordinaryLoss":69000000.0,"incomeBeforeTax":2918000000.0,"incomeTaxes":832000000.0,"netIncome":2085000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2085000000.0,"comprehensiveIncome":1492000000.0,"eps":66.94,"dilutedEps":null,"dividendPerShare":null,"per":18.66,"roe":0.053,"cashFlowFromOperatingActivities":5770000000.0,"depreciationAndCashflowFromOperatingActivities":1774000000.0,"cashFlowFromInvestingActivities":-2616000000.0,"cashFlowFromFinancialActivities":450000000.0,"changesInCashAndCashEquivalents":3547000000.0,"列1":"asr","submitDate":"2020\/12\/18","stockCode":4554,"accountingYear":"第56期（自　2019年10月１日　至　2020年９月30日）","accountingYearStart":"2019\/10\/1","accountingYearEnd":"2020\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2020\/12\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.647,"cashAndCashEquivalents":null,"assets":62913000000.0,"currentAssets":35913000000.0,"fixedAsset":27000000000.0,"tangibleFixedAssets":12942000000.0,"intangibleFixedAssets":2852000000.0,"investmentAndOtherAssets":11204000000.0,"liabilities":22190000000.0,"currentLiabilities":11428000000.0,"shorTermDept":1000000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1640000000.0,"fixedLiabilities":10761000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":7180000000.0,"netAsset":40723000000.0,"capitalStock":40861000000.0,"capital":3799000000.0,"capitalSurplus":5841000000.0,"accumulatedEarnings":31285000000.0,"treasuryStock":-63000000.0,"valuationAndConversionAdjustments":-141000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":9295000000.0,"costOfSales":5260000000.0,"grossProfit":4034000000.0,"sgaExpenses":2336000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1698000000.0,"nonOperatingIncome":44000000.0,"nonOperatingExpenses":10000000.0,"interestExpense":8000000.0,"ordinaryProfit":1732000000.0,"extraordinaryGain":154000000.0,"extraordinaryLoss":1000000.0,"incomeBeforeTax":1885000000.0,"incomeTaxes":556000000.0,"netIncome":1328000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1328000000.0,"comprehensiveIncome":1224000000.0,"eps":42.64,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/2\/8","stockCode":4554,"accountingYear":null,"accountingYearStart":"2020\/10\/1","accountingYearEnd":"2021\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2021\/3\/31","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":15648000.0,"sharesOwendPercent":0.6437,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.52,"cashAndCashEquivalents":10835000000.0,"assets":62563000000.0,"currentAssets":34430000000.0,"fixedAsset":28132000000.0,"tangibleFixedAssets":13672000000.0,"intangibleFixedAssets":2755000000.0,"investmentAndOtherAssets":11704000000.0,"liabilities":29998000000.0,"currentLiabilities":18954000000.0,"shorTermDept":7300000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1840000000.0,"fixedLiabilities":11043000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":7553000000.0,"netAsset":32564000000.0,"capitalStock":32163000000.0,"capital":3799000000.0,"capitalSurplus":4408000000.0,"accumulatedEarnings":24560000000.0,"treasuryStock":-603000000.0,"valuationAndConversionAdjustments":397000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":17277000000.0,"costOfSales":9613000000.0,"grossProfit":7664000000.0,"sgaExpenses":4977000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":861000000.0,"operatingIncome":2686000000.0,"nonOperatingIncome":91000000.0,"nonOperatingExpenses":40000000.0,"interestExpense":18000000.0,"ordinaryProfit":2738000000.0,"extraordinaryGain":154000000.0,"extraordinaryLoss":21000000.0,"incomeBeforeTax":2871000000.0,"incomeTaxes":849000000.0,"netIncome":2022000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2021000000.0,"comprehensiveIncome":2457000000.0,"eps":68.63,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":4405000000.0,"depreciationAndCashflowFromOperatingActivities":978000000.0,"cashFlowFromInvestingActivities":-2018000000.0,"cashFlowFromFinancialActivities":-3653000000.0,"changesInCashAndCashEquivalents":-1206000000.0,"列1":"q2r","submitDate":"2021\/5\/10","stockCode":4554,"accountingYear":null,"accountingYearStart":"2020\/10\/1","accountingYearEnd":"2021\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2021\/6\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.533,"cashAndCashEquivalents":null,"assets":61959000000.0,"currentAssets":33053000000.0,"fixedAsset":28906000000.0,"tangibleFixedAssets":14401000000.0,"intangibleFixedAssets":2576000000.0,"investmentAndOtherAssets":11928000000.0,"liabilities":28963000000.0,"currentLiabilities":18535000000.0,"shorTermDept":7300000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1840000000.0,"fixedLiabilities":10427000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":7093000000.0,"netAsset":32996000000.0,"capitalStock":32444000000.0,"capital":3799000000.0,"capitalSurplus":4409000000.0,"accumulatedEarnings":24839000000.0,"treasuryStock":-603000000.0,"valuationAndConversionAdjustments":549000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":25498000000.0,"costOfSales":14371000000.0,"grossProfit":11126000000.0,"sgaExpenses":7526000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3600000000.0,"nonOperatingIncome":56000000.0,"nonOperatingExpenses":53000000.0,"interestExpense":28000000.0,"ordinaryProfit":3604000000.0,"extraordinaryGain":154000000.0,"extraordinaryLoss":21000000.0,"incomeBeforeTax":3737000000.0,"incomeTaxes":1095000000.0,"netIncome":2641000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2641000000.0,"comprehensiveIncome":3229000000.0,"eps":95.24,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/8\/6","stockCode":4554,"accountingYear":null,"accountingYearStart":"2020\/10\/1","accountingYearEnd":"2021\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2021\/9\/30","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1532.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":16184000.0,"sharesOwendPercent":0.6655,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":1345.56,"equityRatio":0.509,"cashAndCashEquivalents":10199000000.0,"assets":64239000000.0,"currentAssets":34834000000.0,"fixedAsset":29404000000.0,"tangibleFixedAssets":14392000000.0,"intangibleFixedAssets":2397000000.0,"investmentAndOtherAssets":12614000000.0,"liabilities":31557000000.0,"currentLiabilities":20192000000.0,"shorTermDept":7000000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1840000000.0,"fixedLiabilities":11365000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":6633000000.0,"netAsset":32681000000.0,"capitalStock":32246000000.0,"capital":3799000000.0,"capitalSurplus":4409000000.0,"accumulatedEarnings":24628000000.0,"treasuryStock":-590000000.0,"valuationAndConversionAdjustments":432000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":33990000000.0,"costOfSales":19239000000.0,"grossProfit":14751000000.0,"sgaExpenses":11402000000.0,"salaryAndBenefit":null,"depreciationAndSGA":338000000.0,"RDExpenses":2446000000.0,"operatingIncome":3349000000.0,"nonOperatingIncome":30000000.0,"nonOperatingExpenses":129000000.0,"interestExpense":53000000.0,"ordinaryProfit":3250000000.0,"extraordinaryGain":155000000.0,"extraordinaryLoss":34000000.0,"incomeBeforeTax":3371000000.0,"incomeTaxes":938000000.0,"netIncome":2432000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2432000000.0,"comprehensiveIncome":2902000000.0,"eps":90.54,"dilutedEps":null,"dividendPerShare":null,"per":12.92,"roe":0.067,"cashFlowFromOperatingActivities":5993000000.0,"depreciationAndCashflowFromOperatingActivities":1828000000.0,"cashFlowFromInvestingActivities":-2345000000.0,"cashFlowFromFinancialActivities":-5435000000.0,"changesInCashAndCashEquivalents":-1842000000.0,"列1":"asr","submitDate":"2021\/12\/20","stockCode":4554,"accountingYear":"第57期（自　2020年10月１日　至　2021年９月30日）","accountingYearStart":"2020\/10\/1","accountingYearEnd":"2021\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0},{"edinetCode":"E00975","endDate":"2021\/12\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.526,"cashAndCashEquivalents":null,"assets":64047000000.0,"currentAssets":32323000000.0,"fixedAsset":31723000000.0,"tangibleFixedAssets":16634000000.0,"intangibleFixedAssets":2623000000.0,"investmentAndOtherAssets":12466000000.0,"liabilities":30345000000.0,"currentLiabilities":19629000000.0,"shorTermDept":7000000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1840000000.0,"fixedLiabilities":10716000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":6173000000.0,"netAsset":33701000000.0,"capitalStock":33011000000.0,"capital":3799000000.0,"capitalSurplus":4409000000.0,"accumulatedEarnings":25382000000.0,"treasuryStock":-579000000.0,"valuationAndConversionAdjustments":688000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":9446000000.0,"costOfSales":5441000000.0,"grossProfit":4005000000.0,"sgaExpenses":2442000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1562000000.0,"nonOperatingIncome":47000000.0,"nonOperatingExpenses":28000000.0,"interestExpense":23000000.0,"ordinaryProfit":1581000000.0,"extraordinaryGain":null,"extraordinaryLoss":0.0,"incomeBeforeTax":1581000000.0,"incomeTaxes":462000000.0,"netIncome":1118000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1118000000.0,"comprehensiveIncome":1374000000.0,"eps":46.05,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2022\/2\/7","stockCode":4554,"accountingYear":null,"accountingYearStart":"2021\/10\/1","accountingYearEnd":"2022\/9\/30","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00975","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":3799,"settlementDate":"2022\/9\/30","submitterName":"富士製薬工業株式会社","submitterNameEnglish":"Fuji Pharma Co.,Ltd.","submitterNameKana":"フジセイヤクコウギョウカブシキガイシャ","location":"千代田区三番町５番地７","industory":"医薬品","corporateNumber":5010000000000.0}]